# EDGAR Filing Document

**Accession Number:** 0001788028
**File Stem:** 0001104659-23-019776
**Filing Date:** 2023-2
**Character Count:** 15266
**Document Hash:** a7bf0d428220e24c2e67e32b8700c7ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-019776.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001104659-23-019776

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**GROUP MEMBERS**: ROCHE HOLDING LTD

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jasper Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001788028
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 842984849
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91228
- **FILM NUMBER:** 23619363

**BUSINESS ADDRESS:**
- **STREET 1:** 2200 BRIDGE PKWY SUITE #102
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 6505491400

**MAIL ADDRESS:**
- **STREET 1:** 2200 BRIDGE PKWY SUITE #102
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Amplitude Healthcare Acquisition Corp
- **DATE OF NAME CHANGE:** 20190912
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ROCHE FINANCE LTD
- **CENTRAL INDEX KEY:** 0001053942
- **STATE OF INCORPORATION:** V8

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O HOFFMAN LA ROCHE
- **STREET 2:** 124 GRENSACHERSTRASSE CH 4002
- **CITY:** BASEL SWITZERLAND
- **STATE:** V8

**MAIL ADDRESS:**
- **STREET 1:** C/O HOFFMAN LA ROCHE
- **STREET 2:** 124 GRENSACHERSTRASSE CH 4002
- **CITY:** BASEL SWITZERLAND
- **STATE:** V8

---

| | | |
|:---|:---|:---|
| **CUSIP No. <u>471871 103</u>** | **SCHEDULE 13G/A** | **Page 1 of 6** |

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 13G/A**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1 - Exit Filing)\***

JASPER THERAPEUTICS, INC.

(Name of Issuer)

Voting Common Stock, par value, $0.0001 per share

(Title of Class of Securities)

471871 103

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

◻ Rule 13d-1(b)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;⌧ Rule 13d-1(c)

◻ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

| | | |
|:---|:---|:---|
| **CUSIP No. <u>471871 103</u>** | **SCHEDULE 13G/A** | **Page 2 of 6** |

---

---

| | |
|:---|:---|
| **1.** | NAMES OF REPORTING PERSONS |
|  | <br> Roche Finance Ltd |
| **2.** | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) ◻ |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) ◻ |
| **3.** | SEC USE ONLY<br>|
| **4.** | CITIZENSHIP OR PLACE OF ORGANIZATION <br>Switzerland  |

---

---

| | | | |
|:---|:---|:---|:---|
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **5.** | SOLE VOTING POWER | 0 |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **6.** | SHARED VOTING POWER<br>| 4624606 (1) |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **7.** | SOLE DISPOSITIVE POWER<br>| 0 |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
| <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **8.** | SHARED DISPOSITIVE POWER<br>| 4624606 (1) |

---

**9.** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,624,606 (1)

**10.** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 (See Instructions) ◻

**11.** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.2% (2)

**12.** TYPE OF REPORTING PERSON (See Instructions) CO

&nbsp;&nbsp;&nbsp;&nbsp;(1) Roche Finance Ltd ("Roche Finance") is the direct beneficial owner of these securities of the Issuer. Roche Finance is
a wholly-owned subsidiary of Roche Holding Ltd, a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding Ltd
is the indirect beneficial owner of these securities of the Issuer.

&nbsp;&nbsp;&nbsp;&nbsp;(2) On or about January 27, 2023, the Issuer completed a public offering
of 69,000,000 shares of its Voting Common Stock, following which the Issuer had approximately 109,321,864 shares of Voting Common Stock
outstanding, as disclosed in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission on January 25,
2023. As a result of such public offering, the Voting Common Stock beneficially owned by the Reporting Persons equaled approximately 4.2%
of the Issuer's outstanding Voting Common Stock as of January 27, 2023.

---

| | | |
|:---|:---|:---|
| **CUSIP No. <u>471871 103</u>** | **SCHEDULE 13G/A** | **Page 3 of 6** |

---

---

| | |
|:---|:---|
| **1.** | NAMES OF REPORTING PERSONS |
|  | <br> Roche Holding Ltd |
| **2.** | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) ◻ |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) ◻ |
| **3.** | SEC USE ONLY<br>|
| **4.** | CITIZENSHIP OR PLACE OF ORGANIZATION <br>Switzerland  |

---

---

| | | | |
|:---|:---|:---|:---|
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **5.** | SOLE VOTING POWER | 0 |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **6.** | SHARED VOTING POWER<br>| 4624606 (1) |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **7.** | SOLE DISPOSITIVE POWER<br>| 0 |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH |  |  |  |
|  <br> NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON WITH | **8.** | SHARED DISPOSITIVE POWER<br>| 4624606 (1) |

---

**9.** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,624,606 (1)

**10.** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 (See Instructions) ◻

**11.** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.2% (2)

**12.** TYPE OF REPORTING PERSON (See Instructions) CO

&nbsp;&nbsp;&nbsp;&nbsp;(1) Roche Finance Ltd ("Roche Finance") is the direct beneficial owner of these securities of the Issuer. Roche Finance is
a wholly-owned subsidiary of Roche Holding Ltd, a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding Ltd
is the indirect beneficial owner of these securities of the Issuer.

(2) On or about January 27, 2023, the Issuer completed a public offering
of 69,000,000 shares of its Voting Common Stock, following which the Issuer had approximately 109,321,864 shares of Voting Common Stock
outstanding, as disclosed in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission on January 25,
2023. As a result of such public offering, the Voting Common Stock beneficially owned by the Reporting Persons equaled approximately 4.2%
of the Issuer's outstanding Voting Common Stock as of January 27, 2023.

---

| | | |
|:---|:---|:---|
| **CUSIP No. <u>471871 103</u>** | **SCHEDULE 13G/A** | **Page 4 of 6** |

---

---

| | |
|:---|:---|
| **Item 1(a).** | **Name of Issuer:** |

---

Jasper Therapeutics, Inc., a Delaware corporation (the "Issuer").

---

| | |
|:---|:---|
| **Item 1(b).** | **Address of Issuer's Principal Executive Offices:** |

---

2200 Bridge Parkway, Suite #102

Redwood City, CA 94065

**Item 2.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Name of Person Filing: Roche Finance Ltd and Roche Holding Ltd

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Address or principal business office or, if none, residence:

Roche Finance Ltd: Grenzacherstrasse 122, 4070 Basel, Switzerland

Roche Holding Ltd: Grenzacherstrasse 124, 4070 Basel, Switzerland

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Citizenship:

Roche Finance Ltd: Switzerland

Roche Holding Ltd: Switzerland

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Title of Class of Securities: Voting Common Stock, par value, $0.0001 per share

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) CUSIP No.: 471871 103

**Item 3.** **If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable.

**Item 4.** **Ownership:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount beneficially owned by each of the Reporting Persons: 4,624,606 (1)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Percent of class held by each of the Reporting Persons: 4.2% (2)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which each Reporting Person has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or to direct the vote: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or to direct the vote: 4,624,606 (1)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of: 4,624,606 (1)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Roche Finance Ltd ("Roche Finance") is the direct beneficial owner of these securities of the Issuer. Roche Finance is
a wholly-owned subsidiary of Roche Holding Ltd, a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding Ltd
is the indirect beneficial owner of these securities of the Issuer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) On or about January 27, 2023, the Issuer completed a public offering
of 69,000,000 shares of its Voting Common Stock, following which the Issuer had approximately 109,321,864 shares of Voting Common Stock
outstanding, as disclosed in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission on January 25,
2023. As a result of such public offering, the Voting Common Stock beneficially owned by the Reporting Persons equaled approximately 4.2%
of the Issuer's outstanding Voting Common Stock as of January 27, 2023.

---

| | | |
|:---|:---|:---|
| **CUSIP No. <u>471871 103</u>** | **SCHEDULE 13G/A** | **Page 5 of 6** |

---

**Item 5.** **Ownership of Five Percent or Less of a Class:**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ⌧.

On or about January 27, 2023, the Issuer completed a public offering of 69,000,000 shares of its Voting Common Stock, following which the Issuer had approximately 109,321,864 shares of Voting Common Stock outstanding, as disclosed in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission on January 25, 2023. As a result of such public offering, the Voting Common Stock beneficially owned by the Reporting Persons equaled approximately 4.2% of the Issuer's outstanding Voting Common Stock as of January 27, 2023.

**Item 6.** **Ownership of More than Five Percent on Behalf of Another Person:**

Not applicable.

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:**

Roche Finance Ltd is a wholly-owned subsidiary of Roche Holding Ltd.

**Item 8.** **Identification and Classification of Members of the Group:**

Not applicable.

**Item 9.** **Notice of Dissolution of Group:**

Not applicable.

**Item 10.** **Certification:**

Not applicable.

---

| | | |
|:---|:---|:---|
| **CUSIP No. <u>471871 103</u>** | **SCHEDULE 13G/A** | **Page 6 of 6** |

---

**SIGNATURE**

After reasonable inquiry and to the best of their knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated this 13th day of February, 2023.

---

| | |
|:---|:---|
| ROCHE FINANCE LTD | ROCHE FINANCE LTD |
| By: | /s/ Carole Nuechterlein |
| Carole Nuechterlein, Authorized Signatory | Carole Nuechterlein, Authorized Signatory |
| By: | /s/ Peter Trybus |
| Peter Trybus, Authorized Signatory | Peter Trybus, Authorized Signatory |
| ROCHE HOLDING LTD | ROCHE HOLDING LTD |
| By: | /s/ Peter Trybus |
| Peter Trybus, Authorized Signatory | Peter Trybus, Authorized Signatory |
| By: | /s/ Claudia Boeckstiegel |
| Claudia Boeckstiegel, Authorized Signatory | Claudia Boeckstiegel, Authorized Signatory |

---